Recently, the 9th "Maker China" Beijing Small and Medium Enterprises Innovation and Entrepreneurship Competition, also known as "Maker Beijing 2024," concluded successfully. In this prestigious event, which gathered numerous innovative projects and entrepreneurial teams, Beijing Genecradle Therapeutics Technology Co., Ltd. (hereinafter referred to as "Genecradle Therapeutics") stood out among 5,791 outstanding competing projects, winning the Leading Enterprise Special Award and the Third Prize in the Pharmaceutical and Health Industry category, demonstrating strong innovative capabilities and development potential.

The "Maker Beijing 2024" competition for small and medium enterprises was jointly organized by the Beijing Municipal Bureau of Economy and Information Technology, the Beijing Municipal Finance Bureau, and the Zhongguancun Science City Management Committee. The aim is to aggregate entrepreneurial resources, stimulate innovation potential, and discover and cultivate small and medium enterprises with innovative abilities and high growth potential. By promoting the integration of large, medium, and small enterprises, the competition fosters industrial structure optimization and upgrading, giving birth to new industries, models, and drivers, providing strong support for regional economic development. It is an important brand event serving the innovation and entrepreneurship of small and medium enterprises in Beijing.

This year's "Maker Beijing 2024" competition reached new heights, attracting 5,791 project registrations, a 14.61% increase from last year, firmly placing it in the first tier of innovation and entrepreneurship competitions in the Beijing area. The competition covered nine cutting-edge fields, including high-end manufacturing, pharmaceutical health, information technology, future industries, artificial intelligence, and energy materials. After rounds of screening through the preliminary, semi-final, industry final, and championship rounds, Genecradle Therapeutics' "Disruptive Gene Therapy Platform Technology Project for Children's Critical Genetic Diseases" stood out in the competition across all fields.

The awards are not only an affirmation of Genecradle Therapeutics' innovative achievements in the pharmaceutical and health field but also a recognition of the company's long-term commitment to an innovation-driven development strategy. In the future, Genecradle Therapeutics will continue to adhere to its original intention, dedicating itself to the research and application of gene therapy technology, bringing more hope and choices to patients worldwide. The company will also use this opportunity to further strengthen cooperation and communication with industry peers, jointly promoting innovation and development in gene therapy technology and bringing more innovation and breakthroughs to the gene therapy industry and industrial chain.

Click the link below to view the full list of award-winning projects:

"Maker Beijing 2024" Innovation and Entrepreneurship Competition announces the list of award-winning projects in nine major industries.

"Maker Beijing 2024" Innovation and Entrepreneurship Competition announces the list of award-winning projects in the top ten leading enterprise special awards.